Cloning_NN
and_CC
expression_NN
of_IN
the_DT
Epstein-Barr_JJ
virus-encoded_JJ
dUTPase_NN
:_:
patients_NNS
with_IN
acute_JJ
,_,
reactivated_VBN
or_CC
chronic_JJ
virus_NN
infection_NN
develop_VBP
antibodies_NNS
against_IN
the_DT
enzyme_NN
._.

The_DT
gene_NN
encoding_VBG
the_DT
Epstein-Barr_JJ
virus_NN
-LRB-_-LRB-
EBV_NN
-RRB-_-RRB-
-_:
specific_JJ
dUTPase_NN
was_VBD
amplified_VBN
from_IN
virus_NN
DNA_NN
by_IN
PCR_NN
._.

The_DT
active_JJ
enzyme_NN
was_VBD
expressed_VBN
in_IN
Escherichia_FW
coli_FW
and_CC
in_IN
insect_NN
cells_NNS
as_IN
a_DT
non-fusion_JJ
protein_NN
._.

The_DT
protein_NN
from_IN
E._FW
coli_FW
specifically_RB
converted_VBD
dUTP_NN
to_TO
dUMP_NN
and_CC
did_VBD
not_RB
react_VB
with_IN
other_JJ
dNTPs_NNS
or_CC
NTPs_NNS
._.

Preliminary_JJ
experiments_NNS
yielded_VBD
a_DT
Km_NN
value_NN
of_IN
about_RB
0.8_CD
microM_NN
for_IN
dUTP_NN
._.

MAbs_NNS
against_IN
the_DT
dUTPase_NN
reacted_VBD
with_IN
a_DT
protein_NN
of_IN
approximately_RB
31_CD
kDa_NN
in_IN
12-O-tetradecanoyl-phorbol-13-acetate_NN
-LRB-_-LRB-
TPA_NN
-RRB-_-RRB-
-_:
stimulated_VBN
B_NN
cells_NNS
harbouring_VBG
either_CC
type_NN
1_CD
or_CC
type_NN
2_CD
EBV_NN
._.

The_DT
protein_NN
was_VBD
found_VBN
in_IN
untreated_JJ
cells_NNS
at_IN
low_JJ
levels_NNS
,_,
whereas_IN
induction_NN
of_IN
the_DT
lytic_JJ
replication_NN
cycle_NN
by_IN
TPA_NN
treatment_NN
or_CC
by_IN
providing_VBG
the_DT
immediate_JJ
early_JJ
transactivator_NN
BZLF1_NN
in_IN
trans_NN
resulted_VBD
in_IN
increased_VBN
expression_NN
._.

We_PRP
demonstrated_VBD
that_IN
the_DT
virus_NN
dUTPase_NN
isolated_VBN
from_IN
EBV-infected_JJ
cells_NNS
is_VBZ
a_DT
phosphoprotein_NN
._.

The_DT
protein_NN
expressed_VBN
in_IN
insect_NN
cells_NNS
was_VBD
used_VBN
to_TO
test_VB
for_IN
the_DT
presence_NN
of_IN
specific_JJ
antibodies_NNS
in_IN
sera_NN
from_IN
normal_JJ
,_,
healthy_JJ
carriers_NNS
and_CC
from_IN
patients_NNS
with_IN
various_JJ
diseases_NNS
._.

While_IN
the_DT
sera_NN
of_IN
EBV-negative_JJ
individuals_NNS
-LRB-_-LRB-
0\/3_CD
-RRB-_-RRB-
or_CC
healthy_JJ
carriers_NNS
-LRB-_-LRB-
0\/33_CD
-RRB-_-RRB-
did_VBD
not_RB
contain_VB
detectable_JJ
levels_NNS
of_IN
antibodies_NNS
,_,
patients_NNS
with_IN
mononucleosis_NN
-LRB-_-LRB-
5\/18_CD
-RRB-_-RRB-
,_,
chronic_JJ
EBV_NN
infection_NN
-LRB-_-LRB-
2\/7_CD
-RRB-_-RRB-
,_,
EBV_NN
reactivation_NN
-LRB-_-LRB-
7\/20_CD
-RRB-_-RRB-
and_CC
human_JJ
immunodeficiency_NN
virus_NN
infection_NN
-LRB-_-LRB-
5\/24_CD
-RRB-_-RRB-
showed_VBD
elevated_JJ
antibody_NN
titers_NNS
against_IN
the_DT
enzyme_NN
._.

This_DT
indicated_VBD
that_IN
the_DT
dUTPase_NN
is_VBZ
expressed_VBN
during_IN
EBV_NN
replication_NN
and_CC
reactivation_NN
._.

The_DT
enzyme_NN
might_MD
therefore_RB
be_VB
a_DT
potential_JJ
target_NN
for_IN
drug_NN
therapy_NN
under_IN
conditions_NNS
of_IN
active_JJ
DNA_NN
replication_NN
._.

